Immutep
IMMP
#10667
Rank
HK$0.20 B
Marketcap
HK$27.30
Share price
-4.92%
Change (1 day)
89.87%
Change (1 year)

P/E ratio for Immutep (IMMP)

P/E ratio as of November 2026 (TTM): -2.14

According to Immutep's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.14447. At the end of 2026 the company had a P/E ratio of -1.09.

P/E ratio history for Immutep from 2016 to 2018

PE ratio at the end of each year

Year P/E ratio Change
2026-1.09268.08%
2025-0.2972-29.74%
2024-0.423018.87%
2023-0.3558-9.71%
2022-0.3941-25.84%
2021-0.5314118.58%
2020-0.24319.65%
2019-0.2217-34.52%
2018-0.33864.94%
2017-0.3226311.69%
2016-0.0784-51.5%
2015-0.1616-16.77%
2014-0.1941-41.24%
2013-0.3304-17.71%
2012-0.4015

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Illumina
ILMN
34.8-1,723.47%๐Ÿ‡บ๐Ÿ‡ธ USA
FibroGen
FGEN
0.1816-108.47%๐Ÿ‡บ๐Ÿ‡ธ USA
HTG Molecular Diagnostics
HTGM
-0.0169-99.21%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.